Pharsight

Drugs that contain Mitapivat Sulfate

1. Pyrukynd patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(6 years from now)

USRE49582 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(6 years from now)

US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(8 years from now)

US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(8 years from now)

US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(8 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Oct, 2032

(8 years from now)

US11793806 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Apr, 2033

(9 years from now)

US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators
Oct, 2038

(14 years from now)

US11878049 AGIOS PHARMS INC Mitapivat therapy and modulators of cytochrome P450
Jul, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 17, 2029
New Chemical Entity Exclusivity (NCE) Feb 17, 2027

NCE-1 date: 2026-02-17

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the t...

Dosage: TABLET;ORAL

More Information on Dosage

PYRUKYND family patents

Family Patents